title: Clarification of linaclotide pharmacology presented in a recent clinical study of plecanatide.
authors.affiliation: Ironwood Pharmaceuticals, Inc., 301 Binney Street, Cambridge, MA, 02142, USA, rbusby@ironwoodpharma.com.
authors.forename: Robert W
authors.initials: RW
authors.lastname: Busby
authors.forename: Stephan
authors.initials: S
authors.lastname: Ortiz
mesh_terms: D005765:Gastrointestinal Agents / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D045265:Natriuretic Peptides / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology*; D017461:Receptors, Atrial Natriuretic Factor / Q000819:agonists*
chemical_list: D005765:Gastrointestinal Agents; D045265:Natriuretic Peptides; D010455:Peptides; C584575:plecanatide; D017461:Receptors, Atrial Natriuretic Factor; C073616:atrial natriuretic factor receptor C; C523483:linaclotide